Factor II and fibrinogen for treatment of haemostatic disorders
AssigneeMedImmune, LLC
InventorsAnn Lovgren, Kenny Hansson
Life of this patent
Estimating the term…
Abstract
The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
Claims16
A method of normalizing impaired haemostasis associated with dilutional coagulopathy in a mammal in need thereof comprising administering a clotting factor treatment selected from the group consisting of:
- (1) recombinant human FII (rhFII), (2) a combination of rhFII and recombinant human FVIIa (rhVIIa), (3) a combination of rhFII, rhVIIa, and recombinant human FX (rhFX), (4) fibrinogen and a combination of rhFII, rhFVIIa, and rhFX, (5) fibrinogen and rhFII, and (6) fibrinogen and a combination of rhFII and rhVIIa,
- wherein administration of said clotting factor treatment is performed without co-administration of any other coagulation factors selected from human coagulation factors FV-FXIII.
A method of normalizing impaired haemostasis associated with dilutional coagulopathy in a mammal in need thereof, the method comprising administering a clotting factor treatment selected from the group consisting of:
- (1) recombinant human FII (rhFII), and (2) fibrinogen and rhFII;
- wherein fibrinogen is administered at a dose of 12.5 to 200 mg/kg, rhFII is administered at a dose of 1 to 10 mg/kg and administration of said clotting factor treatment is performed without co-administration of any other coagulation factors from among the human coagulation factors FV-FXIII.
Dependencies are inferred from the claim text.